Pharmacy Practice News - Is Compounding ‘Denial Coma’ Over?

Pharmacy Practice News - Is Compounding ‘Denial Coma’ Over?

Florida Article Is a Must Read: Gives Ideas for States to Improve Regulation and It Notes Anytime FDA Has attempted to Rein In Compounders Who Act As Manufacturers Courts Have Blocked IT

See prior post or read article entitled 950 FL Pharmacies Called High-Risk Compounders
  here 

950 FL Pharmacies Called High-Risk Compounders

By Carol Gentry

Originally published on Thu January 31, 2013 1:19 pm

Almost 950 Florida-licensed pharmacies engage in “sterile compounding,” the type of high-risk drug-making that led to a deadly fungal meningitis epidemic last year, according to a Department of Health survey released last week.
Sterile compounders are now given priority for state inspections, but it’s going to be a daunting task to check them all, judging from the survey report and interviews with pharmacists and health department officials. There are  two reasons:
--One-third of the 950 are based out of state, like the New England Compounding Center, the source of contaminated drugs that caused the epidemic. Florida law doesn’t give health officials any authority over out-of-state licensees.
--While the state has 18 inspectors for pharmacies, the health department said, only five of them are licensed pharmacists. And even the pharmacists need extra training to inspect the high-risk sterile compounders, officials said

Continue reading here

NEW & REVISED DRAFT GUIDANCE CDER FDA PLANS TO PUBLISH in 2013: COMPOUNDING IS ON THE LIST

Guidance Agenda:
New & Revised Draft Guidances CDER is
Planning to Publish During
Calendar Year 2013
(See the Good Guidance Practices (GGPs) regulation on this Web page or
21 CFR 10.115 for details about the Guidance Agenda.)
CATEGORY — Advertising
•
Considerations for Regulatory Submissions of Promotional Labeling and Advertising Materials including Submissions in Electronic Format
CATEGORY — Animal Rule
•
Product Development Under the Animal Rule
CATEGORY — Biopharmaceutics
•
Food-Effect Bioavailability and Fed Bioequivalence Studies---Bioavailability and Bioequivalence Studies for Orally Administered Drug Products Submitted in New Drug Applications General Consideration
CATEGORY — Biosimilarity
•
Submission of Clinical Pharmacology Data as Evidence of Biosimilarity for Biologics and Protein Products
CATEGORY — Chemistry
•
Allowable Excess Volume and Labeled Vial Fill Size
•
Bioequivalence Studies with Pharmacokinetic Endpoints for Drug Products Submitted in Abbreviated New Drug Applications
•
CMC Postapproval Manufacturing Changes Reportable in Annual Reports for Specified Biological Products
•
Comparability Protocols for Approved Drugs: Chemistry, Manufacturing, and Controls Information
•
Elemental Impurities in Drug Products Marketed in the United States
•
Immunogenicity Considerations for Low Molecular Weight Heparin
•
Liposome Drug Products: CMC, Human Pharmacokinetic and Bioavailability; and Labeling Documentation
•
Size and Physical Attributes of Generic Tablets
Version: 01.31.13
CATEGORY — Clinical/Antimicrobial
•
Antibacterial Therapies for Patients with Limited or No Alternative Therapies for the Treatment of Serious Bacterial Diseases
•
Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment
•
Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment
•
Pulmonary Tuberculosis: Developing Drugs for Treatment
CATEGORY — Clinical/Medical
•
Alzheimer’s Disease: Developing Drugs for the Treatment of Early State Disease
•
Common Issues in Drug Development for Rare Diseases
•
Developing Drug and Biological Products for Analgesic Indications
•
Modifications and Revisions of Risk Evaluation and Mitigation Strategies (REMS)
•
Pregnant Women in Clinical Trials – Scientific and Ethical Considerations
CATEGORY – CMC and CLINICAL/MEDICAL
•
Immunogenicity Assessment for Therapeutic Protein Products
CATEGORY — Clinical Pharmacology
•
Bioanalytical Methods Validation
•
Clinical Pharmacogenomics: Study Design and Premarketing Evaluation
•
Clinical Pharmacology Consideration for Therapeutics Proteins
•
General Clinical Pharmacology Considerations for Pediatrics Studies for Drugs and Biological Products
CATEGORY — Clinical/Statistical
•
Multiple Endpoints in Clinical Trials
CATEGORY — Current Good Manufacturing Practices (CGMPs)/Compliance
•
Quality Systems Approach to Pharmaceutical cGMP Regulation (OMPQ)
•
Uniformity of In-Process Mixtures (OMPQ)
•
Control of Highly Potent Compounds (OMPQ)
•
Contract Manufacturing Arrangements for Drugs: Quality Agreements
•
Submission of Field Alert Reports and Biological Product Deviation Reports (OMPQ)
•
Pre-Launch Activities Importation Request (PLAIR)
Version: 01.31.13
CATEGORY — Drug Safety Information
•
Best Practices in Developing Proprietary Names to Minimize Medication Errors
•
Providing Postmarket Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report)
•
Safety Considerations in Product Design to Minimize Medication Errors.
•
Securing the Drug Supply Chain—Standards for Tracking and Tracing Prescription Drug Packages
•
Safety Considerations for Container Label and Carton Labeling Design to Minimize Medication Errors
CATEGORY — Electronic Submissions
•
Providing Regulatory Submissions in Electronic Format – General Considerations
•
Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications
•
Providing Regulatory Submissions in Electronic Format – Postmarketing Safety Reports
•
Providing Regulatory Submissions in Electronic Format – Standardized Study Data
•
Providing Submissions in Electronic Format – Summary Level Clinical Site Data for CDER’s Inspection Planning
•
Providing Submissions in Electronic Format – Postmarket Non-Expedited Individual Case Safety Reports; Technical Questions and Answers
CATEGORY — IND
•
Adverse Events: Collection and Reporting for Secondary Endpoints
CATEGORY — Labeling
•
Drug Names and Dosage Forms
•
Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
CATEGORY – Pharmacology/Toxicology
•
Endocrine Disruption Potential of Drugs: Non Clinical Evaluation
CATEGORY — Procedural
•
Applying the Criteria for Requiring a Risk Evaluation and Mitigation Strategy (REMS)
•
Expedited Programs for Serious Conditions, Drugs and Biologics
•
Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants
•
Integrated Summary of Safety
•
Investigational New Drug Applications prepared and submitted by Clinical Sponsor Investigators
•
Pediatric Product Development
Version: 01.31.13
Version: 01.31.13
•
Pharmacy Compounding of Human Drugs Under Section 503A of the Federal Food, Drug, and Cosmetic Act
•
Public Disclosure of FDA-Sponsored Studies
•
Prescription Drug Marketing Act (PDMA) Requirements
•
Reporting Drug Sample Distribution Under Section 6004 of the Affordable Care Act
•
Use of a Master File for Shared System Risk Evaluation and Mitigation Strategies
•
Electronic Source Data in Clinical Investigations
Note: Agenda items reflect guidances under development as of the date of this posting.

Source found  here

Pharmalot Discussion on Supreme Court's Ruling that Pharmaceutical Sales Representatives Are Not Entitled To Overtime Pay

To read this excellent review, click here